Northern Trust
TRDA icon

Northern Trust’s Entrada Therapeutics TRDA Stock Holding History

Northern Trust’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Buy
309,942
+74,950
+32% +$719K ﹤0.01% 3056
2026
Q1 		$2.97M Buy
234,992
+8,691
+4% +$99.6K ﹤0.01% 2751
2025
Q4 		$2.33M Sell
226,301
-27,306
-11% -$230K ﹤0.01% 2909
2025
Q3 		$1.47M Sell
253,607
-46,714
-16% -$273K ﹤0.01% 3199
2025
Q2 		$2.02M Sell
300,321
-9,866
-3% -$79.4K ﹤0.01% 2982
2025
Q1 		$2.8M Sell
310,187
-7,990
-3% -$99.6K ﹤0.01% 2742
2024
Q4 		$5.5M Buy
318,177
+70,497
+28% +$1.28M ﹤0.01% 2455
2024
Q3 		$3.96M Buy
247,680
+57,371
+30% +$904K ﹤0.01% 2614
2024
Q2 		$2.71M Sell
190,309
-9,033
-5% -$128K ﹤0.01% 2742
2024
Q1 		$2.82M Sell
199,342
-1,346
-0.7% -$19K ﹤0.01% 2786
2023
Q4 		$3.03M Sell
200,688
-4,373
-2% -$64.8K ﹤0.01% 2771
2023
Q3 		$3.24M Buy
205,061
+10,967
+6% +$173K ﹤0.01% 2678
2023
Q2 		$2.94M Buy
194,094
+160,701
+481% +$2.21M ﹤0.01% 2791
2023
Q1 		$484K Sell
33,393
-967
-3% -$12.9K ﹤0.01% 3479
2022
Q4 		$465K Buy
34,360
+4,363
+15% +$76.5K ﹤0.01% 3532
2022
Q3 		$473K Buy
29,997
+13,669
+84% +$174K ﹤0.01% 3538
2022
Q2 		$199K Sell
16,328
-73,930
-82% -$561K ﹤0.01% 3930
2022
Q1 		$847K Buy
90,258
+10,775
+14% +$116K ﹤0.01% 3505
2021
Q4 		$1.36M Buy
+79,483
New +$1.93M ﹤0.01% 3413

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Northern Trust's TRDA Position: Q2 2026 in Review

Northern Trust increased its Entrada Therapeutics (TRDA) stake by 32% in Q2 2026, buying an estimated $719K and bringing the position to 309,942 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Northern Trust first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $5.5M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Northern Trust held 309,942 shares of Entrada Therapeutics worth $2.28M as of Q2 2026.
  • Northern Trust bought 74,950 Entrada Therapeutics shares in Q2 2026, an estimated $719K.
  • Entrada Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3056 holding.
  • Northern Trust first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Northern Trust's Entrada Therapeutics position peaked at $5.5M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.